Suzette Girgis
Johnson & Johnson (United States)(US)Jazz Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis
Most-Cited Works
- → Teclistamab in Relapsed or Refractory Multiple Myeloma(2022)1,022 cited
- → Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study(2011)912 cited
- → Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma(2022)599 cited
- → Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study(2021)298 cited
- → Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma(2012)84 cited
- → Diphenylhydantoin‐induced Gingival Hyperplasia: its Relationship to Dose and Serum Level(1973)61 cited